NLRP3 inflammasome inhibitors are described in a Zomagen Biosciences Ltd. patent and are reported to be useful for the treatment of autoimmune, cardiovascular, inflammatory, liver, lung, metabolic and neurological disorders.
Hanmi Holdings Co. Ltd. has reported novel skeletal derivatives acting as HER2 mutant inhibitors and thus reported to be useful or the treatment of cancer.
Eli Lilly & Co. has disclosed new calcium/calmodulin-dependent 3’,5’-cyclic nucleotide phosphodiesterase 1 (PDE1) inhibitors reported to be useful for the treatment of chronic kidney disease, Alzheimer’s disease, Parkinson’s disease, schizophrenia, heart failure, pulmonary hypertension, myocardial infarction and ischemic stroke, among others.
Work at Laekna Therapeutics Shanghai Co. Ltd. has led to the identification of new bicyclic heteroaromatic compounds acting as Myt1 kinase (PKMYT1) inhibitors potentially useful for the treatment of cancer.
Heart failure with preserved ejection fraction (HFpEF) is a disease in which the left ventricle (LV) of the heart shows impaired relaxation during cardiac diastole, often accompanied by structural and functional abnormalities.
Researchers from Sanofi SA reported the preclinical characterization of SAR-446159 (ABL-301), a bispecific antibody construct comprising an antibody targeting α-synuclein fused to an engineered antibody fragment that targets IGF-1R and functions as a blood-brain barrier (BBB) shuttle, known as the Grabody-B platform.
Sepsis-induced coagulopathy (SIC) is a complication of sepsis tied to high mortality in patients. Anticoagulation using a coagulation factor IIa and Xa dual inhibitor might have the potential to improve the treatment of this severe condition.
BDNF is the brain’s most abundant neurotrophic factor, playing a key role in neuronal survival and synaptic plasticity through the activation of the transcription factor CREB, which is essential for driving beneficial effects in neurons. CREB is downregulated in Parkinson’s disease, Huntington’s disease, frontotemporal dementia, Alzheimer’s disease and other neurodegenerative conditions.
Ignite Biomedical Inc. and Liquid Biosciences have announced the discovery of biomarkers to diagnose substance use disorder (SUD). The set of biomarkers includes some that have not previously been associated with addiction and spans all 6 SUDs (opioid, cocaine, methamphetamine, alcohol, nicotine and cannabis use disorders).
RSS
